TNXP vs. NRSN, EDSA, VINC, FLGC, TRAW, HUGE, PIRS, RDHL, PPBT, and KPRX
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include NeuroSense Therapeutics (NRSN), Edesa Biotech (EDSA), Vincerx Pharma (VINC), Flora Growth (FLGC), Traws Pharma (TRAW), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), RedHill Biopharma (RDHL), Purple Biotech (PPBT), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical preparations" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Tonix Pharmaceuticals presently has a consensus target price of $5.50, indicating a potential upside of 2,689.05%. Given Tonix Pharmaceuticals' higher possible upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than NeuroSense Therapeutics.
Tonix Pharmaceuticals' return on equity of -83.03% beat NeuroSense Therapeutics' return on equity.
Tonix Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 1 mentions for NeuroSense Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.43 beat NeuroSense Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.
NeuroSense Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tonix Pharmaceuticals received 337 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 63.84% of users gave Tonix Pharmaceuticals an outperform vote.
Summary
Tonix Pharmaceuticals beats NeuroSense Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
